ADRA2A and melanoma: For each disease, we first searched for literature evidence about the top 15 predicted targets unobserved in the known biological networks (Tables G and H in S1 Text) and then chose six target candidates that lacked existing literature support for further experimental validation, including HSP90AB1, RPS6KB1, and MME for melanoma, and ADCY5, ADRA2A, and EEF2 for CRC.